Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02038881
Recruitment Status : Completed
First Posted : January 17, 2014
Results First Posted : April 2, 2020
Last Update Posted : April 2, 2020
Sponsor:
Information provided by (Responsible Party):
Bavarian Nordic

Brief Summary:
The main purpose of this clinical trial is to generate additional safety data in a highly immunocompromised population. HIV-infected persons are considered excellent candidates to represent the highly immunocompromised population for enrolment in this trial. Additionally, the immune system's response (protection against smallpox as measured by the amount of antibodies produced) following injections of MVA-BN® smallpox vaccine will be evaluated. All participants in this trial will be randomly and evenly assigned to one of three groups to receive two, three or four injections. Group 1 will receive the standard regime consisting of one dose at each vaccination time point, Group 2 will receive two doses at each vaccination time point and Group 3 will receive a booster vaccination 12 weeks after the standard vaccination schedule with MVA-BN® smallpox vaccine. Participation in the trial is scheduled to last up to 75 weeks.

Condition or disease Intervention/treatment Phase
Smallpox Biological: IMVAMUNE® Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 87 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Actual Study Start Date : April 28, 2014
Actual Primary Completion Date : May 10, 2017
Actual Study Completion Date : May 10, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS Smallpox

Arm Intervention/treatment
Experimental: Group 1 (standard regimen)
One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
Biological: IMVAMUNE®
0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
Other Names:
  • IMVANEX®
  • MVA-BN® smallpox vaccine

Experimental: Group 2 (double dose regimen)
Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
Biological: IMVAMUNE®
0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
Other Names:
  • IMVANEX®
  • MVA-BN® smallpox vaccine

Experimental: Group 3 (booster regimen)
One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
Biological: IMVAMUNE®
0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
Other Names:
  • IMVANEX®
  • MVA-BN® smallpox vaccine




Primary Outcome Measures :
  1. Number of Participants With SAEs [ Time Frame: within 75 weeks ]
    Occurrence, relationship and intensity of any serious AE (SAE)


Secondary Outcome Measures :
  1. Number of Participants With AESIs [ Time Frame: within 75 weeks ]
    Occurrence, relationship to the trial vaccine, and intensity of any adverse event of special interest (AESI)

  2. Number of Participants With Related Grade >=3 Adverse Events [ Time Frame: within 29 days after any vaccination ]
    Number of Participants with any Grade >=3 Adverse Event probably, possibly, or definitely related to the study vaccine. Pooled solicited and unsolicited AEs.

  3. Number of Unsolicited Non-serious Adverse Events: Relationship to Vaccination [ Time Frame: within 29 days after any vaccination ]
    Occurrence of unsolicited non-serious AEs by relationship to study vaccine

  4. Number of Unsolicited Non-serious Adverse Events: Intensity [ Time Frame: within 29 days after any vaccination ]
    Occurrence of unsolicited non-serious AEs by Intensity

  5. Number of Participants With Solicited Local Adverse Events [ Time Frame: within 8 days after any vaccination ]
    Number of participants with solicited local AEs (redness, swelling, induration, pruritus, and pain) by intensity. Percentages based on subjects with at least one completed diary card. [Injection site erythema, injection site swelling and injection site induration--all sizes measured in diameter with max severity of: 0=0, 1 = <30 mm, 2 = ≥30 - <100 mm, 3 = ≥100 mm. Injection site pruritus: 0=absent, 1=mild, 2=moderate, 3=severe. Injection site pain: 0=absent, 1=painful to touch, 2=painful when limb is moved, 3=spontaneously painful/prevents normal activity.]

  6. Number of Participants With Solicited General AEs [ Time Frame: within 8 days after any vaccination ]
    Number of Participants with solicited systemic/general AEs (pyrexia, headache, myalgia, nausea, fatigue, and chills) by intensity. Percentages based on subjects with at least one completed diary card. [Body temperature: 0 = <99.5 F (<37.5 C), 1 = ≥99.5 - <100.4 F (≥37.5 - <38.0 C), 2= ≥100.4 - <102.2 F (≥38.0 - <39.0 C), 3= ≥102.2 - <104.0 F (≥39.0 - <40.0 C), 4= ≥ 104.0 F (≥40.0 C); pyrexia is defined as oral temperature ≥ 100.4 F (≥ 38.0 C).] [Headache, myalgia, nausea, chills and fatigue: 0 = none, 1 = mild: easily tolerated, minimal discomfort and no interference with daily activity, 2 = moderate: some interference with daily activity, 3 = severe: prevents daily activity.]

  7. CD4+ T Cell Counts [ Time Frame: within 15 days after each vaccination ]
    Mean CD4+ T-cell counts over time

  8. Geometric Mean Titers (GMT) Measured by Enzyme-linked Immunosorbent Assay (ELISA) at All Immunogenicity Sampling Points [ Time Frame: within 64 weeks ]
    GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.

  9. ELISA GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined)) [ Time Frame: Week 6 ]
    GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.

  10. ELISA GMT 2 Weeks Following the Last Vaccination [ Time Frame: Week 6 (Groups 1 and 2), Week 14 (Group 3) ]
    GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.

  11. ELISA GMT During Follow-up [ Time Frame: Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3) ]
    GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.

  12. GMTs Measured by Plaque Reduction Neutralization Test (PRNT) at All Immunogenicity Sampling Points [ Time Frame: within 64 weeks ]
    GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.

  13. PRNT GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined)) [ Time Frame: Week 6 ]
    GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.

  14. PRNT GMT 2 Weeks Following the Last Vaccination [ Time Frame: Week 6 (Groups 1 and 2), Week 14 (Group 3) ]
    GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.

  15. PRNT GMT During Follow-up [ Time Frame: Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3) ]
    GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.

  16. Percentage of Participants With Seroconversion by ELISA [ Time Frame: within 64 weeks ]
    SC rate based on ELISA. SC is defined as the appearance of antibody titers >= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  17. Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined)) [ Time Frame: Week 6 ]
    SC rate based on ELISA. SC is defined as the appearance of antibody titers >= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  18. Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Last Vaccination [ Time Frame: Week 6 (Groups 1 and 2), Week 14 (Group 3) ]
    SC rate based on ELISA. SC is defined as the appearance of antibody titers >= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  19. Percentage of Participants With Seroconversion by ELISA During Follow-up [ Time Frame: Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3) ]
    SC rate based on ELISA. SC is defined as the appearance of antibody titers >= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  20. Percentage of Participants With Seroconversion by PRNT [ Time Frame: within 64 weeks ]
    SC rate based on PRNT. SC is defined as the appearance of antibody titers >= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  21. Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined)) [ Time Frame: Week 6 ]
    SC rate based on PRNT. SC is defined as the appearance of antibody titers >= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  22. Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Last Vaccination [ Time Frame: Week 6 (Groups 1 and 2), Week 14 (Group 3) ]
    SC rate based on PRNT. SC is defined as the appearance of antibody titers >= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.

  23. Percentage of Participants With Seroconversion by PRNT During Follow-up [ Time Frame: Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3) ]
    SC rate based on PRNT. SC is defined as the appearance of antibody titers >= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects aged between 18-45 years, vaccinia-naïve.
  2. HIV-1 infection documented by ELISA and confirmed by Western blot at any time prior to study entry. HIV-1 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), HIV-1 culture, HIV-1 antigen, plasma HIV-1 ribonucleic acid (RNA), or a second antibody test other than ELISA is acceptable as an alternative test at any time prior to study entry.
  3. On stable antiretroviral therapy (ART) i.e. Combination ART for at least 6 months. Subject must be on the same ART regimen for at least 12 weeks with no change prior to enrollment in this clinical trial.
  4. Screening HIV-1 RNA < 200 copies/ml by US Food and Drug Administration (FDA) approved PCR assay within 45 days prior to study entry.
  5. Current CD4 counts ≥ 100 cells/µl ≤ 500 cells/µl.
  6. Documented nadir CD4 count < 200 cells/µl at any time prior to enrollment.
  7. Hemoglobin ≥ 9.0 g/dl for female subjects, ≥ 10.0 g/dl or male subjects.
  8. Platelets ≥ 100,000/mm3.
  9. Ability and willingness of subject to provide written informed consent.
  10. Body Mass Index (BMI) ≥ 18.5 and < 35 kg/m2.
  11. Women of childbearing potential (WOCBP) must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the trial, and must avoid becoming pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal (defined as ≥ 12 months without a menstrual period) or surgically sterilized. Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products).
  12. WOCBP must have a negative serum pregnancy test at screening (SCR) and a negative urine pregnancy test within 24 hours prior to each vaccination.
  13. Absolute neutrophil count cells ≥ 750/mm3.
  14. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) > 60 ml/min as estimated by the Cockcroft-Gault equation.

    1. For men: (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dl x 72) = CrCl (ml/min)
    2. For women: multiply the result by 0.85 = CrCl (ml/min).Adequate hepatic function defined as: Total bilirubin ≤ 2 x upper limit normal (ULN) in the absence of other evidence of significant liver disease
  15. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤ 2.5 x ULN.
  16. Troponin I < 2 x ULN at entry in the clinical trial.
  17. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two premature ventricular contractions (PVC) in a row, ST elevation consistent with ischemia).

Exclusion Criteria:

  1. Pregnant or breast-feeding women.
  2. Typical vaccinia scar.
  3. Known or suspected history of smallpox vaccination.
  4. History of vaccination with any poxvirus-based vaccine.
  5. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy.
  6. History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject or would limit the subject's ability to complete the trial including uncontrolled diabetes as according to the 'Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events' Version 1.0, December 2004, Clarification August 2009.
  7. History of or active autoimmune disease, persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
  8. Known or suspected impairment of immunologic function except those defined in the inclusion criteria, including, but not limited to clinically significant liver disease, diabetes mellitus type I and moderate to severe kidney impairment.
  9. History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.
  10. History or clinical manifestation of clinically significant and severe hematological, pulmonary, central nervous, cardiovascular or gastrointestinal disorders (except HIV infection, chronic or active Hepatitis-B-Virus or Hepatitis-C-Virus infection).
  11. Clinically significant psychiatric disorder not adequately controlled by medical treatment.
  12. History of coronary heart disease, myocardial infarction, angina pectoris, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, or any other heart condition under the care of a doctor.
  13. Known history of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before age 50 years.
  14. Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof). NOTE: This criterion applies only to subjects 20 years of age and older.
  15. Current alcohol abuse (40 g/day for at least 6 month) and/or intravenous and/or intranasal drug abuse (within the past 6 months).
  16. Known allergy to MVA-BN® vaccine or any of its constituents, e.g. tris (hydroxymethyl)-amino methane, including known allergy to egg or aminoglycosides.
  17. History of anaphylaxis or severe allergic reaction to any vaccine.
  18. Acute disease (illness with or without a fever) at the time of enrollment.
  19. Body temperature ≥ 100.4°F (≥ 38.0°C) at the time of enrollment.
  20. Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior to or after trial vaccination.
  21. Having received any vaccinations or planned vaccinations with a killed vaccine within 14 days prior to or after trial vaccination.
  22. Use of immunosuppressant or immunomodulatory agents including systemic glucocorticoids (excluding nasal or inhaled steroids), tacrolimus, sirolimus, rapamycin, mycophenolate, cyclosporine, TNF-alpha blockers or antagonists, azathioprine, interferon, growth factors, or intravenous immunoglobulin in the 60 days prior to enrollment in this clinical trial.
  23. Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
  24. Administration or planned administration of immunoglobulins and/or any blood products during a period starting from three months prior to administration of the vaccine and ending at last physical trial visit.
  25. Use of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the first dose of the trial vaccine, or planned administration of such a drug during the trial period.
  26. Trial personnel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02038881


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Arkansas
Health for Life Clinic Little Rock
Little Rock, Arkansas, United States, 72207
United States, California
Quest Clinical Research
San Francisco, California, United States, 94115
United States, District of Columbia
Dupont Circle Physicians Group
Washington, District of Columbia, United States, 20009
United States, Florida
Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL
Pensacola, Florida, United States, 32504
Rowan Tree Medical
Wilton Manors, Florida, United States, 33305
United States, Illinois
University of Illinois - Chicago
Chicago, Illinois, United States, 60612
United States, Iowa
University of Iowa Departments of Internal Medicine and Microbiology University of Iowa
Iowa City, Iowa, United States, 52242
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Pennsylvania
University of Pennsylvania Clinical Trials Unit
Philadelphia, Pennsylvania, United States, 19104
Puerto Rico
Clinical Research Puerto Rico, Inc.
San Juan, Puerto Rico, 009091711
Fundacion de Investigacion
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
Bavarian Nordic
Investigators
Layout table for investigator information
Principal Investigator: Edgar T Overton, MD University of Alabama at Birmingham
  Study Documents (Full-Text)

Documents provided by Bavarian Nordic:
Study Protocol  [PDF] November 18, 2014
Statistical Analysis Plan  [PDF] May 5, 2015

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bavarian Nordic
ClinicalTrials.gov Identifier: NCT02038881    
Other Study ID Numbers: POX-MVA-037
First Posted: January 17, 2014    Key Record Dates
Results First Posted: April 2, 2020
Last Update Posted: April 2, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Smallpox
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Poxviridae Infections
DNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs